Human CCL22 / MDC Protein, Fc Tag

ユーザーレビュー
製品番号/仕様
価格
数量
CC2-H5257-20ug
$185.00
CC2-H5257-50ug
$370.00
CC2-H5257-1mg
$3400.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Synonyms

    MDC, ABCD-1, SCYA22, STCP-1, DC, B-CK, A-152E5.1

  • Source

    Human CCL22, Fc Tag (CC2-H5257) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Gln 93 (Accession # O00626-1).

    Predicted N-terminus: Gly 25

    Request for sequence
  • Molecular Characterization

    CCL22 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 34.5 kDa. The protein migrates as 35-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, 0.2 M Arginine, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    CCL22 SDS-PAGE

    Human CCL22, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

ユーザーレビュー
コメントを投稿

バックグランド

MDC is the high-affinity ligand for CCR4. Secreted by tumor-associated macrophages and dendritic cells, CCL22 recruits immunosuppressive CCR4+ Tregs into the tumor microenvironment. This chemokine axis dampens anti-tumor immunity, and its blockade aims to exclude Tregs and unleash effector T-cell responses.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    ATP Binding Cassette Subfamily D Member 1

  • カテゴリ:

  • 市販の医薬品数:

    1 詳細

  • 治験医薬品数:

    2 詳細

  • 最新の開発ステージ:

    Approved

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8